- Khiron Life Science Corp. (News)
TORONTO, Nov. 19, 2018
Quotas represent progress towards cultivating strains for commercial purposes in Q1 of 2019
TORONTO, Nov. 19, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, is pleased to announce that it has received additional quotas from the Colombian Technical Quotas Group ("TQG"), to cultivate 5,040 psychoactive cannabis plants for the purposes of completing the Colombian Agricultural Institute ("ICA") agronomic evaluation tests. This represents a key milestone towards Khiron's stated timeline to bring medical cannabis options to market in Colombia.